BD and Ypsomed are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe.
The new syringe includes a shorter, 8-millimeter needle and thinner wall cannulas to support the delivery of higher volume and viscosity medicines. The company said these enhancements should enable improved injection time and optimized flow, addressing common challenges with large-volume biologics and enabling drug developers to move beyond the limitations of standard syringe offerings.
Large‑volume (greater than 1 mL) subcutaneous injections of biologics are increasingly common in areas such as oncology, autoimmune diseases, rare diseases, and metabolic disorders. Ypsomed's YpsoMate 5.5, introduced in 2022, was developed to meet this need.
BD and Ypsomed have a history of collaboration, beginning with the BD Neopak XtraFlow 2.25mL Glass Prefillable Syringe and YpsoMate 2.25 autoinjector.
